The TGA has knocked back an application to allow OTC sales of combination budesonide/formoterol inhalers for as-needed reliever therapy in people with mild asthma. In rejecting the application for pharmacy sales, the TGA acknowledged there was evidence that a combination of long-acting beta-agonist (LABA) with inhaled corticosteroid (ICS) was potentially safer for as-needed use in ...
TGA rejects proposal for OTC sales of budesonide/formoterol inhalers
By Michael Woodhead
8 Feb 2021